In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, discusses how the tariffs impact the reshoring of manufacturing services, alongside the strategies that pharma leaders can use in order to start shoring up their supply chains.
The latest news for pharma industry insiders.
The US president delays tariffs that comply with the 2020 USMCA for one month, with reciprocal tariffs still expected to go into effect by April 2.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, describes how the software company’s solution can help deliver better patient outcomes and substantial savings for healthcare plans, employers, and members alike.
The latest news for pharma industry insiders.
The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering access to academic and startup communities.
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, shares the strategies that should be taken to overcome health information exchange blockages.
NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.
Ron Lanton, Partner, Lanton Law, examines the legal and economic impacts of reciprocal tariffs on the pharma supply chain, including potential disruptions and increased drug costs.
The latest news for pharma industry insiders.
The 25% tax on various imports have gone into effect, resulting in retaliatory tariffs from the impacted nations.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, describes how PBMs financially benefit from generics, and why a completely open generic market powered by cash would be beneficial.
The latest news for pharma industry insiders.
Why meaningful content must meet the right audience.
In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, comments on health policy developments that the pharma supply chain should be aware of.
The latest news for pharma industry insiders.
After an initial 30-day pause, the US president plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China.
Tracy Lopez uncovers the fundamentals pertaining to third-party logistics providers.
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, describes how the tariffs can affect price or competition within the branded drug space.
The latest news for pharma industry insiders.
The news comes amid the possibility that President Trump imposes a 25% tariff on pharmaceuticals, which could encourage manufacturers to begin reshoring their services.
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, details the factors that could makes the generic drug market susceptible to supply chain disruptions.
The presidential action follows up on a 2019 final rule aimed at empowering patients and boosting competition among hospitals, group health plans, and health insurance issuers in both individual and group markets.
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, outlines how the tax on goods coming from China and potential 25% tariff on pharmaceuticals could influence generic drug prices.
The latest news for pharma industry insiders.
Patients who utilize the self-pay pharmacy will also be receiving savings on select sizes.
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, comments on why he believes polypharmacy is an overlooked driver of unnecessary spending and adverse health outcomes.
The latest news for pharma industry insiders.
